Efferent Labs has inked a deal with Evotec to develop its implantable biosensor technology. The device, which is injected into a patient or lab animal, contains living cells to measure cellular function in vivo. Click here to read the full article
(BUFFALO, NY) Apr. 1, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in
(BUFFALO, NY) Feb. 15, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in
(CHARLESTON, S.C.) Mar 6, 2021/GlobeNewswire/ – Today, Efferent Labs announces an expanded development
Efferent Labs offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Efferent Labs® offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Sign up for email alerts of Press Releases and Efferent Labs’ breaking news
